Paper Details

  1. Home
  2. Paper Details

Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.

Author: BoonP, ChauvelP, OtoulC, Pohlmann-EdenB, WroeS

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Levetiracetam is an effective and well-tolerated add-on therapy for patients with refractory partial seizures. Both 1000 mg/day and 2000 mg/day doses of levetiracetam significantly reduced seizure frequency compared to placebo, with a greater responder rate for the higher dose. The most common side effects were headache, asthenia, infection, somnolence, pharyngitis, dizziness, and pain.
Paper Details　
Original Abstract of the Article :
PURPOSE: To evaluate the efficacy, dose-response, tolerability, and withdrawal effects of levetiracetam (Keppra) as adjunctive therapy in adult patients with partial epilepsy. METHODS: In this European multicenter, double-blind, randomized, cross-over trial, levetiracetam 1000 or 2000 mg/day given ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0920-1211(01)00323-0

データ提供：米国国立医学図書館（NLM）

Levetiracetam: A Dose-Dependent Solution for Partial Epilepsy

Partial epilepsy, a type of seizure disorder, often requires adjunctive therapy to effectively manage seizures. This study aimed to evaluate the efficacy and dose-response effects of levetiracetam (Keppra) as an adjunctive therapy in adult patients with refractory partial seizures. The researchers conducted a double-blind, randomized, cross-over trial involving 324 patients, comparing different doses of levetiracetam to placebo.

Levetiracetam: A Dose-Dependent Approach to Seizure Control

The study revealed that levetiracetam, in both 1000 mg and 2000 mg daily doses, significantly reduced mean partial seizure frequency compared to placebo. Importantly, the study found a dose-dependent response, with the higher dose demonstrating a greater responder rate. These findings suggest that levetiracetam can be an effective treatment option for partial epilepsy, with dose adjustments potentially optimizing seizure control.

Navigating the Desert of Epilepsy

This study provides valuable information for clinicians managing patients with partial epilepsy. It underscores the potential of levetiracetam as a safe and effective treatment option, with a dose-dependent response. This research reminds us that finding the right dose can be critical in achieving optimal therapeutic outcomes. Like a wise traveler navigating a vast desert, clinicians need to carefully tailor their approach to ensure the best possible care for their patients.

Dr.Camel's Conclusion

The desert of epilepsy can be a challenging and unpredictable landscape. This study offers a valuable roadmap for clinicians, demonstrating the efficacy and dose-dependent response of levetiracetam. It's a testament to the ongoing search for better treatments to manage this complex condition. By understanding the nuances of drug therapy, clinicians can provide their patients with a smoother journey through the desert of epilepsy.
Date :
  1. Date Completed 2002-04-02
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

11823112

DOI: Digital Object Identifier

10.1016/s0920-1211(01)00323-0

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.